Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)
Small Cell Lung Carcinoma
DRUG: Durvalumab|DRUG: Olaparib
Progression-free survival (PFS), PFS according to investigator-assessed RECIST 1.1 from start of maintenance therapy, Approximately two years (from First patient in (FSI) to Last patient last visit (LSLV))
Incidence, severity and grading of adverse events (AE) and seriouse adverse events (SAE)., Grading is based on CTCAE Version 5, Approximately two years (from FSI to LSLV)|ORR of maintenance., Grading is based on RECIST 1.1, Approximately two years (from FSI to LSLV)
Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)